+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants



Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants



HIV Clinical Trials 7(2): 70-85



ESPRIT, is a phase III, open-label, randomized, international clinical trial evaluating the effects of subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART) versus ART alone on HIV-disease progression and death in HIV-1-infected individuals with CD4+ T-cells > or =300 cells/microL. To describe the baseline characteristics of participants randomized to ESPRIT overall and by geographic location. Baseline characteristics of randomized participants were summarized by region. 4,150 patients were enrolled in ESPRIT from 254 sites in 25 countries. 41%, 27%, 16%, 11%, and 5% were enrolled in Europe, North America, South America, Asia, and Australia, respectively. The median age was 40 years, 81% were men, and 76%, 11%, and 9% were Caucasian, Asian, and African American or African, respectively. 44% of women enrolled (n = 769) were enrolled in Thailand and Argentina. Overall, 55% and 38% of the cohort acquired HIV through male homosexual and heterosexual contact, respectively. 25% had a prior history of AIDS-defining illness; Pneumocystis jirovecii pneumonia, M. tuberculosis, and esophageal candida were most commonly reported. Median nadir and baseline CD4+ T-cell counts were 199 and 458 cells/muL, respectively. 6% and 13% were hepatitis B or C virus coinfected, respectively. Median duration of antiretroviral therapy (ART) was 4.2 years; the longest median duration was in Australia (5.2 years) and the shortest was in Asia (2.3 years). 17%, 13%, and 69% of participants began ART before 1995, between 1996 and 1997, and from 1998 onward, respectively. 86% used ART from two or more ART classes, with 49% using a protease inhibitor-based regimen and 46% using a nonnucleoside reverse transcriptase inhibitor-based regimen. 78% had plasma HIV RNA below detection (<500 cp/mL). ESPRIT has enrolled a diverse population of HIV-infected individuals including large populations of women and patients of African-American/African and Asian ethnicity often underrepresented in HIV research. As a consequence, the results of the study may have wide global applicability.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048993118

Download citation: RISBibTeXText

PMID: 16798622

DOI: 10.1310/hct.2006.7.2.005


Related references

Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (Esprit): Geographical and Gender Differences in the Baseline Characteristics of Participants. Hiv Clinical Trials 7(2): 70-85, 2006

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Controlled Clinical Trials 23(2): 198-220, 2002

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Medicine 12(4): 219-227, 2011

Differences in baseline characteristics and 1-year psychological factors between participants and non-participants in the randomized, controlled trial regarding patient-led follow-up after rectal cancer (FURCA). Acta Oncologica 58(5): 627-633, 2019

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal 199: 170-175, 2018

Randomized intervention trial on preventive home visits to older people: baseline and follow-up characteristics of participants and non-participants. Scandinavian Journal of Public Health 35(4): 410-417, 2007

Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. Yearbook of Pulmonary Disease 2012: 82-83, 2012

Baseline characteristics of participants in the randomized national lung screening trial. Journal of the National Cancer Institute 102(23): 1771-1779, 2010

Baseline Characteristics and Generalizability of Participants in an Internet Smoking Cessation Randomized Trial. Annals of Behavioral Medicine 50(5): 751-761, 2016

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology 4(3): 273-286, 2019

Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovascular Diseases 10(2): 147-150, 2000

Baseline and follow-up characteristics of participants and nonparticipants in a randomized clinical trial of multifactorial fall prevention in Denmark. Journal of the American Geriatrics Society 57(10): 1844-1849, 2009

Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prevention Research 5(12): 1381-1393, 2012

Baseline and Follow-Up Characteristics of Participants and Nonparticipants in a Randomized Clinical Trial of Multifactorial Fall Prevention in Denmark. Yearbook of Sports Medicine 2010: 369-370, 2010

Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: The Physicians' Health Study. Controlled Clinical Trials 23(6): 686-702, 2002